The Malaysian Reserve

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Vaccine Was Safe and Well Tolerated at the Maximum Tolerated DoseResults Support Advancement of the Program into Phase 2 DevelopmentCombination of ...